TP53 and neoplasm: The latest promising preclinical studies also revealed that APC/β-catenin pathway could be targeted by TNIK (TRAF and NCK-interacting protein kinase) inhibition [4], while gain of function of TP53 is also an emerging potential target for tumor cells with TP53 mutation [5, 6].